Indicating Growing Adoption Of Ayurveda, Public Sector Manufacturer Of AYUSH Medicines Posts Record Turnover For FY21

Indicating Growing Adoption Of Ayurveda, Public Sector Manufacturer Of AYUSH Medicines Posts Record Turnover For FY21A Representative Image. (Website/Beauty Smart Care)

Indian Medicines Pharmaceutical Corporation Limited (IMPCL), the public sector manufacturing unit of the Ministry of Ayurveda, Yoga, Naturopathy, Unani, Siddha and Homoeopathy (AYUSH) has recorded a turnover of Rs 164.33 crore for the financial year 2020-21.

This is the highest number achieved in the company’s history and an all-time high profit of approximately Rs 12 crore is reported for the year. In the previous year 2019-20 best revenue figures of the company was Rs 97 crore.

This growth is reflective of the fast-growing adoption of AYUSH products and services by the public in the wake of Covid-19 pandemic, the Ministry of AYUSH said in a statement.

Adding another feather in IMPCL’s cap, the World Health Organisation (WHO) recently recommended its 18 Ayurvedic products for WHO-GMP/COPP certification subject to certain observations in March 2021.

This certification is an endorsement of the quality of IMPCL’s products. It will help IMPCL to commence export operation of quality medicines at a global level.

Presently, IMPCL is manufacturing 656 classical Ayurvedic, 332 Unani and 71 proprietary Ayurvedic medicines for the various diseases spectrum. It has contributed towards research and development activities and 25 new proprietary ayurvedic medicines as per the Essential Drug List (EDL).

Every government institution doing business with IMPCL has praised the company for providing steady support to various health programmes and ensuring an unbroken supply of products during the Covid-19 pandemic.